
Overview
Background
Associate Professor Victoria Atkinson is both a Senior Medical Oncologist and a Principal Investigator for clinical trials in the adjuvant and metastatic setting at the Princess Alexandra Hospital and Greenslopes Private Hospital (in collaboration with Gallipoli Medical Research Foundation). Additionally, she is an Associate Professor with the University of Queensland, Clinical School of Medicine. Associate Professor Atkinson’s research interests are in the field of Oncology, and she has extensive experience in targeted-therapies and immunotherapies. Her main research interests are melanoma and gastro-intestinal oncology. Associate Professor Atkinson is passionate about trying to improve outcome for all patients with advanced melanoma as well as advanced gastro-intestinal cancers.
Associate Professor Atkinson has been involved in the clinical development of the current targeted and immunotherapies in melanoma over the past decade bringing these therapies into clinical practice. She has been involved in advocating for patient access to these therapies for patients in Queensland and Australia from guidelines through to reimbursement policies. These therapies have revolutionised the lives of patients and brought about the longest median overall survival for advanced melanoma. However there still remains significant work to be done in therapy resistant disease and she continues to work with therapies towards overcoming resistance.
In the past 5 years, Associate Professor Atkinson has been an Invited Speaker at 22 national and international meetings including Medical Oncology Group of Australia ASM Immunotherapy Symposium, New Zealand Society for Medical Oncology meeting and the Society for Melanoma Research congress. A/Prof Atkinson has published 82 publications, 31 oral abstracts and 65 posters. Associate Professor Atkinson is actively involved in the research supervision of her basic and advanced trainees, and resident medical officers who demonstrate interest in a project. She has supervised trainees to complete their research projects and supported 6 Australian research poster presentations, and 10 international research poster presentations.
She is passionate and motivated to continue to change practice by bringing clinically important and relevant trials to Queensland and to mentor trainees and junior consultants to continue this tradition.
Availability
- Professor Victoria Atkinson is:
- Available for supervision
Research interests
-
Oncology
-
Melanoma
-
Gastro-intestinal oncology
-
Patient outcomes
Works
Search Professor Victoria Atkinson’s works on UQ eSpace
2024
Journal Article
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Eggermont, Alexander M. M., Kicinski, Michal, Blank, Christian U., Mandala, Mario, V. Long, Georgina, Atkinson, Victoria, Dalle, Stephane, Haydon, Andrew, Meshcheryakov, Andrey, Khattak, Adnan, Carlino, Matteo S., Sandhu, Shahneen, Larkin, James, Puig, Susana, Ascierto, Paolo A., Rutkowski, Piotr, Schadendorf, Dirk, Boers-Sonderen, Marye, Di Giacomo, Anna Maria, van den Eertwegh, Alfonsus J. M., Grob, Jean-Jacques, Gutzmer, Ralf, Jamal, Rahima, van Akkooi, Alexander C. J., Lorigan, Paul, Grebennik, Dmitri, Kreplere, Clemens, Marreaud, Sandrine, Suciu, Stefan and Robert, Caroline (2024). Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. European Journal of Cancer, 211 114327. doi: 10.1016/j.ejca.2024.114327
2024
Journal Article
Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238
Weber, Jeffrey, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Maria, De La Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Larkin, James (2024). Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238. Journal of Clinical Oncology, 42 (31), 3702-3712. doi: 10.1200/JCO.23.01448
2024
Journal Article
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Bührer, Emanuel, Kicinski, Michal, Mandala, Mario, Pe, Madeline, Long, Georgina V, Atkinson, Victoria, Blank, Christian U, Haydon, Andrew, Dalle, Stéphane, Khattak, Adnan, Carlino, Matteo S, Meshcheryakov, Andrey, Sandhu, Shahneen, Puig, Susana, Schadendorf, Dirk, Jamal, Rahima, Rutkowski, Piotr, van den Eertwegh, Alfonsus J M, Coens, Corneel, Grebennik, Dmitri, Krepler, Clemens, Robert, Caroline and Eggermont, Alexander M M (2024). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 25 (9), 1202-1212. doi: 10.1016/S1470-2045(24)00338-3
2024
Journal Article
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Blank, Christian U., Lucas, Minke W., Scolyer, Richard A., van de Wiel, Bart A., Menzies, Alexander M., Lopez-Yurda, Marta, Hoeijmakers, Lotte L., Saw, Robyn P. M., Lijnsvelt, Judith M., Maher, Nigel G., Pulleman, Saskia M., Gonzalez, Maria, Acosta, Alejandro Torres, van Houdt, Winan J., Lo, Serigne N., Kuijpers, Anke M. J., Spillane, Andrew, Klop, W. Martin C., Pennington, Thomas E., Zuur, Charlotte L., Shannon, Kerwin F., Seinstra, Beatrijs A., Rawson, Robert V., Haanen, John B. A. G., Ch'ng, Sydney, Naipal, Kishan A. T., Stretch, Jonathan, van Thienen, Johannes V., Rtshiladze, Michael A. ... Long, Georgina V. (2024). Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. New England Journal of Medicine, 391 (18), 1696-1708. doi: 10.1056/NEJMoa2402604
2024
Journal Article
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
Hepner, Adriana, Versluis, Judith M., Wallace, Roslyn, Allayous, Clara, Brown, Lauren Julia, Trojaniello, Claudia, Gerard, Camille Lea, Jansen, Yanina JL, Bhave, Prachi, Neyns, Bart, Haydon, Andrew, Michielin, Olivier, Mangana, Joanna, Klein, Oliver, Shoushtari, Alexander N., Warner, Allison Betof, Ascierto, Paolo Antonio, McQuade, Jennifer Leigh, Carlino, Matteo S., Zimmer, Lisa, Lebbe, Celeste, Johnson, Douglas B., Sandhu, Shahneen, Atkinson, Victoria, Blank, Christian U., Lo, Serigne N., Long, Georgina V. and Menzies, Alexander M. (2024). The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. European Journal of Cancer, 196 113441. doi: 10.1016/j.ejca.2023.113441
2023
Journal Article
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Mallardo, Domenico, Woodford, Rachel, Menzies, Alexander M., Zimmer, Lisa, Williamson, Andrew, Ramelyte, Egle, Dimitriou, Florentia, Wicky, Alexandre, Wallace, Roslyn, Mallardo, Mario, Cortellini, Alessio, Budillon, Alfredo, Atkinson, Victoria, Sandhu, Shahneen, Olivier, Michielin, Dummer, Reinhard, Lorigan, Paul, Schadendorf, Dirk, Long, Georgina V., Simeone, Ester and Ascierto, Paolo A. (2023). The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. Journal of Translational Medicine, 21 (1) 753. doi: 10.1186/s12967-023-04607-4
2023
Journal Article
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
Goodman, Rachel S., Di Guardo, Lorenza, Maurichi, Andrea, Kirwin, Brendan, Khattak, Adnan, Vanella, Vito, Lee, Joanna, Lawless, Aleigha, Czapla, Juliane, Spagnoletti, Andrea, Ambrosini, Margherita, Livingstone, Elisabeth, Long, Georgina V., Sullivan, Ryan J., Carlino, Matteo S., Atkinson, Victoria, Trojanello, Claudia, Ascierto, Paolo A., Schadendorf, Dirk, Warburton, Lydia, Menzies, Alexander M., Santinami, Mario and Johnson, Douglas B. (2023). Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal of Cancer, 194 113354, 113354. doi: 10.1016/j.ejca.2023.113354
2023
Journal Article
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Arance, Ana, de la Cruz-Merino, Luis, Petrella, Teresa M., Jamal, Rahima, Ny, Lars, Carneiro, Ana, Berrocal, Alfonso, Márquez-Rodas, Ivan, Spreafico, Anna, Atkinson, Victoria, Costa Svedman, Fernanda, Mant, Andrew, Khattak, Muhammad A., Mihalcioiu, Catalin, Jang, Sekwon, Cowey, C Lance, Smith, Alan D., Hawk, Natalyn, Chen, Ke, Diede, Scott J., Krepler, Clemens and Long, Georgina V. (2023). Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Journal of Clinical Oncology, 41 (1), 75-85. doi: 10.1200/JCO.22.00221
2023
Conference Publication
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial
Khattak, Adnan, Weber, Jeffrey S., Meniawy, Tarek, Taylor, Matthew H., Ansstas, George, Kim, Kevin B., McKean, Meredith, Long, Georgina V., Sullivan, Ryan J., Faries, Mark B., Tran, Thuy, Cowey, Charles Lance, Medina, Theresa Michelle, Segar, Jennifer Margaret, Atkinson, Victoria, Gibney, Geoffrey Thomas, Luke, Jason J., Buchbinder, Elizabeth Iannotti, Meehan, Robert S., Carlino, Matteo S. and on behalf of Moderna Author's Group (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.17_suppl.LBA9503
2023
Journal Article
Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy
Thompson, Jake R., Lai-Kwon, Julia, Morton, Rachael L., Guminski, Alexander D., Gonzalez, Maria, Atkinson, Victoria, Sandhu, Shahneen, Brown, Michael P., Menzies, Alexander M., Mcarthur, Grant A., Lo, Serigne N., Long, Georgina V. and Bartula, Iris (2023). Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy, 15 (8), 593-610. doi: 10.2217/imt-2022-0262
2023
Journal Article
Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia
Burgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631
2023
Journal Article
Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Weber, Jeffrey S., Schadendorf, Dirk, Del Vecchio, Michele, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Brown, Michael P., Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, De La Cruz-Merino, Luis, Van Der Westhuizen, Andre, Menzies, Alexander M. ... Long, Georgina V. (2023). Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology, 41 (3), 517-527. doi: 10.1200/JCO.22.00533
2023
Journal Article
Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy
Sandhu, Shahneen, Atkinson, Victoria, Cao, Maria González, Medina, Theresa, Rivas, Ainara Soria, Menzies, Alexander M., Caro, Ivor, Roberts, Louise, Song, Yuyao, Yan, Yibing, Guo, Yu, Xue, Cloris and Long, Georgina V. (2023). Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy. European Journal of Cancer, 178, 180-190. doi: 10.1016/j.ejca.2022.10.019
2023
Journal Article
Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey
Thompson, Jake R., Fu, Hong, Saw, Robyn P. M., Sherman, Kerry A., Beedle, Victoria, Atkinson, Victoria, Boyle, Frances, O’Sullivan, Niamh A., Martin, Linda K. and Bartula, Iris (2023). Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey. Quality of Life Research, 32 (12), 3531-3545. doi: 10.1007/s11136-023-03492-0
2023
Journal Article
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes
Lee, Joanna, Ahmed, Tasnia, Maurichi, Andrea, Di Guardo, Lorenzo, Stagno, Anna M., Warburton, Lydia, Taylor, Amelia. M., Livingstone, Elisabeth, Rehman, Saba, Khattak, Adnan, Kahler, Katharina C., Vanella, Vito, Atkinson, Victoria, Millward, Michael, Schadendorf, Dirk, Johnson, Douglas B., Ascierto, Paolo A., Hauschild, Axel, Lo, Serigne N., Long, Georgina V., Menzies, Alexander M. and Carlino, Matteo S. (2023). BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. European Journal of Cancer, 179, 87-97. doi: 10.1016/j.ejca.2022.11.009
2022
Journal Article
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
Larkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Mandalá, Mario (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 173, 285-296. doi: 10.1016/j.ejca.2022.06.041
2022
Conference Publication
Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma
Aoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357
2022
Journal Article
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study
Dimitriou, F., Namikawa, K., Reijers, I. L.M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C. J., Zaman, F., Haydon, A., Carvajal, R. D., Hamid, O., Dummer, R., Hauschild, A. ... Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33 (9), 968-980. doi: 10.1016/j.annonc.2022.06.004
2022
Journal Article
In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case series
Sanjida, Saira, Betz-Stablein, Brigid, Atkinson, Victoria, Janda, Monika, Barsoum, Ramez, Edwards, Harrison Aljian, Chiu, Frank, Tran, My Co, Soyer, H. Peter and Schaider, Helmut (2022). In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case series. Cancers, 14 (11) 2801, 2801. doi: 10.3390/cancers14112801
2022
Conference Publication
Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer
Iqbal, Samreen, Atkinson, Victoria, Arneil, Melissa, Andelkovic, Vladimir and Roberts, Kate Elizabeth (2022). Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer. 2022 ASCO Annual Meeting, Chicago, IL United States, 3-7 June 2022. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2022.40.16_suppl.e16033
Supervision
Availability
- Professor Victoria Atkinson is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Professor Victoria Atkinson's areas of expertise, story ideas and help finding experts, contact our Media team: